Navigation Links
Promise for Soya Allergy Sufferers

Two Chinese soybean lines that grow without the primary protein linked to soy allergies in children and adults have been isolated by scientists//.

The two lines already are adapted to Illinois-like conditions and will be given away to breeders seeking to produce new varieties of allergy-free soybeans without genetic engineering.

Crop scientists at the University of Illinois at Urbana-Champaign and the USDA-Agricultural Research Service's Donald Danforth Plant Science Center in St. Louis screened more than 16,000 soybean lines kept in the USDA's National Soybean Germplasm Collection. The findings will appear later this year in the journal Crop Science.

The two soybean lines (PI 567476 and PI 603570A) contain virtually identical genetic mutations that do not contain the leading allergy-causing P34 protein, which consists of 379 amino acids, said Theodore Hymowitz, emeritus professor of plant genetics in the crop sciences department at the U. of I.

‘We are releasing this information with no patents so that companies and breeders involved with soybeans can incorporate these two lines as quickly as possible,’ Hymowitz said. Companies in Japan, Canada and across the United States have been following the research effort, he added.

The research, which was funded primarily by the Illinois-Missouri Biotechnology Alliance, went through two stages.

First, using a specially developed immunochemistry approach, Hymowitz's post-doctoral assistant Leina M. Joseph examined 100 lines of soybeans per day for nine months from the UI-based collection. Seeds were crushed, treated and placed on a membrane for screening. A second screening using stronger antibodies and protein gels was done to confirm the absence of P34 in the two domestic lines, Joseph said.

After the two lines were isolated, seeds were sent to the Danforth Center for additional molecular analysis to determine why P34 was absent. Six ident ical genetic mutations were found in each, indicating the two lines may be related, Hymowitz said.

‘The lack of the protein was confirmed by more-detailed two-dimensional protein assays,’ said Eliot M. Herman, a lead scientist at Danforth who probed the seeds with post-doctoral researcher Monica A. Schmidt. ‘We then isolated the gene responsible for the lesion, and we found there was a single significant change in the gene's sequence that likely produced a protein which could not be made as a stable product.’

Herman discovered P34 in the early 1990s and in 2003 had successfully used a gene-silencing technique to create a soybean line in which P34 was ‘knocked out.’ However, because of public resistance to genetically modified products researchers have been seeking a more traditional approach. Because the newly identified lines occur naturally, they can be successfully crossed into other soybean lines ‘without any biotechnology-derived component,’ the researchers noted.

‘Soybeans are slowly but surely increasingly being used in the foods we eat, and with that we are noticing an increase in the number of children and adults that have allergies to soybeans,’ Hymowitz said.

Currently, 6 percent to 8 percent of children are allergic to soy-based products, including infant formulas, while 2 percent of adults have had allergic reactions, which range from harmless skin reactions and gastrointestinal irritation to more serious facial swelling, shortness of breath, difficulty swallowing and fainting.

Avoiding soy products is becoming more difficult because of soy's use as fillers and components of many menu items. While people can read labels before preparing meals at home, avoiding soy at restaurants isn't as easy, Hymowitz said.


Related medicine news :

1. New Prostate Cancer Vaccine Shows Promise
2. Ebola Treatment Shows Promise
3. Stem Cells Found To Offer Promise For Hair Growth
4. Promised Drug Doesnt Help Acute Heart Failure
5. Marijuana-Derived Drug Promises Hope In Treating Bladder Infection
6. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
7. New Pancreatic Cancer Vaccine Holds Promise
8. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
9. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
10. Maternal Vitamin D Supplementation Promises Healthy Bones In Child
11. Cervical Cancer Vaccine Show Promise In Prevention
Post Your Comments:

(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: